Pfizer

FDA authorizes first COVID-19 vaccine shots for toddlers under age five

The regulatory body has now approved Moderna shots for school-aged children and teens as well.

published on : 17th June 2022

Pfizer offers low-cost drugs to poor nations

The drugmaker announced the program Wednesday at the World Economic Forum’s annual gathering in Davos, Switzerland, and said it was aimed at improving health equity in 45 lower-income countries.

published on : 25th May 2022

Three COVID vaccine shots protect children under five years of age: Pfizer

It aims to give tots an even lower dose - just one-tenth of the amount adults receive - but discovered during its trial that two shots didn't seem quite strong enough for preschoolers.

published on : 23rd May 2022

Pfizer to spend USD 11.6B on migraine treatment maker Biohaven

The New York drugmaker said Tuesday it will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has another nasal spray under development.

published on : 10th May 2022

Tamil Nadu gets Pfizer’s biggest Asian drug hub

While this centre will be a part of a network of 12 global centres set up worldwide, it is the first and only one at present being set up by Pfizer in Asia.

published on : 5th May 2022

Pfizer to seek Covid booster for healthy 5- to 11-year-olds

In a small study, 140 youngsters who'd already gotten two shots were given a booster six months later, and researchers found the extra shot generally revved up their immune response.

published on : 15th April 2022

Moderna seeks FDA authorization for 4th dose of Covid shot  

Moderna said its request for an additional dose was based on “recently published data generated in the United States and Israel following the emergence of Omicron.”

published on : 18th March 2022

Pfizer seeking OK for 4th COVID dose for seniors, say sources

It's not that good against infections, but doesn't last very long. But we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer, source added.

published on : 16th March 2022

South Korea approves Pfizer's COVID vaccine for ages 5-11

More than 500 virus patients are now in serious or critical condition, up from around 200 in mid-February.

published on : 23rd February 2022

South Korean officials approve Pfizer's COVID vaccine for ages 5-11

The 99 new deaths were the highest daily tally since December 31, when the country was grappling with a delta-driven surge that buckled hospital systems.

published on : 23rd February 2022

Vaccine sales push Pfizer earnings beyond expectations in final quarter

Pfizer's two-shot coronavirus vaccine brought in $36.78 billion in revenue in 2021, its first full year on the market.

published on : 8th February 2022

Singapore approves Pfizer's Paxlovid pill for COVID-19 treatment

When administered within five days of the onset of symptoms, the Paxlovid pill reduces that risk by 87.8 per cent.

published on : 3rd February 2022

Pfizer begins testing omicron-matched COVID shots in adults

COVID-19 vaccine-makers have been updating their shots to better match omicron in case global health authorities decide the change is needed.

published on : 26th January 2022

Sputnik V Covid vaccine shows higher Omicron-specific antibodies than Pfizer: Study

The joint Russian-Italian study compared the blood serum samples of people taken three to six months after the second dose of the two vaccines.

published on : 21st January 2022

Two doses of Sputnik provide two times higher antibodies against Omicron than Pfizer vaccine: Study

The study was conducted at the Italian Spallanzani Institute on comparable groups of sera from individuals vaccinated with Sputnik V and Pfizer.

published on : 20th January 2022
1 2 3 4 5 >